P. V. Bonanno

发表

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

R. Banzi, M. Jakovljevic, B. Wettermark, 2021, BioMed research international.

Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries

R. Banzi, B. Wettermark, B. Godman, 2022, Frontiers in Pharmacology.

The Expiry of Humira

I. Huys, E. Allocati, A. Vulto, 2021 .

Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case study with olaratumab.

Renata Curi Hauegen, S. Simoens, C. Nadal, 2019 .

Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Steven Simoens, Brian Godman, Guenka Petrova, 2019, Generics and Biosimilars Initiative Journal.

Medicines management in the palliative care of cancer patients

P. V. Bonanno, Ian Mifsud, 2015 .

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

A. Haycox, S. Simoens, B. Godman, 2017, Front. Pharmacol..

Towards a framework for the continual improvement of healthcare

P. V. Bonanno, C. Mackie, 2002 .

Structured Expert Judgement for Decisions on Medicines Policy and Management

B. Godman, A. Morton, P. V. Bonanno, 2020 .

Policies for biosimilar uptake in Europe: An overview

S. Simoens, I. Huys, S. Spillane, 2018 .

Utilisation of the ESMO-MCBS in practice of HTA.

B. Godman, C. Wild, A. Bucsics, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The managed entry of new drugs into a National Health Service: a case study for Malta.

P. V. Bonanno, 2003 .

Patients' lived experiences with antineoplastic medicines for the management of malignant solid tumours: A systematic review.

D. Stewart, A. Weidmann, P. V. Bonanno, 2020, Research in social & administrative pharmacy : RSAP.